Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655838 | 0.80 | LMNA (0.56) | LMNAGAAKDM4EMAPTTHRB | |
| SCHEMBL1401005 | 0.78 | LMNA (0.54) | LMNAGAAKDM4EMAPTTHRB | |
| SCHEMBL1254224 | 0.78 | LMNA (0.67) | LMNAGAACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5932995 | 0.76 | LMNA (0.64) | LMNAGAAKDM4EMAPTTHRB | |
| SCHEMBL11485692 | 0.76 | LMNA (0.52) | LMNAGAAKDM4EMAPTTHRB | |
| SCHEMBL8166082 | 0.76 | LMNA (0.64) | LMNAGAACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11485695 | 0.76 | LMNA (0.52) | LMNAGAAKDM4EMAPTTHRB | |
| SCHEMBL8998922 | 0.76 | LMNA (0.64) | LMNAGAACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2000856 | 0.76 | LMNA (0.52) | LMNAGAAKDM4EMAPTTHRB | |
| SCHEMBL8998925 | 0.76 | LMNA (0.64) | LMNAGAACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2198858-B1 | Sustained release preparation of a macrolide compound like tacrolimus | ASTELLAS PHARMA INC (JP) | 2011-06-29 | — | — | EP | claimed |
| EP-1064942-B9 | SUSTAINED RELEASE PREPARATION OF A MACROLIDE | FUJISAWA PHARMACEUTICAL CO (JP) | 2011-03-02 | — | — | EP | claimed |
| EP-1421939-B9 | Sustained release preparation of a macrolide compound like tacrolimus | ASTELLAS PHARMA INC (JP) | 2011-03-02 | — | — | EP | claimed |
| EP-2198858-A1 | Sustained release preparation of a macrolide compound like tacrolimus | Astellas Pharma Inc. (JP) | 2010-06-23 | — | — | EP | claimed |
| EP-1421939-B1 | Sustained release preparation of a macrolide compound like tacrolimus | ASTELLAS PHARMA INC (JP) | 2010-04-21 | — | — | EP | claimed |
| US-20050169993-A1 | Sustained-release formulation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-04 | — | — | US | claimed |
| US-6833353-B1 | Inhibiting matrix metalloprotease (MMP) production using such as tacrolimus, cyclosporing A or 33-epi-chloro-33-desoxy-ascomycin | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-21 | — | — | US | claimed |
| US-20040220204-A1 | Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases | ASTELLAS PHARMA INC. (FORMERLY YAMANOUCHI PHARMACEUTICAL CO., LTD.) (JP) | 2004-11-04 | — | — | US | claimed |
| EP-1064942-B1 | SUSTAINED RELEASE PREPARATION OF A MACROLIDE | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-06-16 | — | — | EP | claimed |
| EP-1421939-A1 | Sustained release preparation of a macrolide compound like tacrolimus | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-26 | — | — | EP | claimed |
| US-20020061907-A1 | Medicinal compositions | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-23 | — | — | US | claimed |
| EP-1074255-A1 | MEDICINAL COMPOSITIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-02-07 | — | — | EP | claimed |
| US-5952478-A | Intermediates for dinucleotide and oligonucleotide analogues | NOVARTIS FINANCE CORPORATION (US) | 1999-09-14 | — | — | US | claimed |
| EP-0778843-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | Novartis AG (CH) | 1997-06-18 | — | — | EP | claimed |
| US-5508270-A | Nucleoside phosphinate compounds and compositions | CIBA-GEIGY CORPORATION (US) | 1996-04-16 | — | — | US | claimed |
| WO-1996008503-A1 | INTERMEDIATES FOR DINUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | NOVARTIS AG (CH) | 1996-03-21 | — | — | WO | claimed |
| EP-0614906-A1 | Mononucleotide analogues and intermediates therefor | CIBA-GEIGY AG (CH) | 1994-09-14 | — | — | EP | claimed |
| US-5034542-A | Preparation of macrolide compounds | AMERICAN CYANAMID COMPANY (US) | 1991-07-23 | — | — | US | claimed |
| EP-0427680-A1 | Heteroatoms-containing tricyclic compounds | SANDOZ LTD. (CH) | 1991-05-15 | — | — | EP | claimed |
| EP-0346133-A2 | Process for the preparation of macrolide compounds | AMERICAN CYANAMID COMPANY (US) | 1989-12-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220204-A1 | Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases | DSG1, DSP, DECR2 | LMNA 1394/4885GAA 1274/4885KDM4E 3875/4885 |
| US-20020061907-A1 | Medicinal compositions | SLC10A2, ABCG2, HDAC10 | LMNA 2736/4885GAA 668/4885KDM4E 3488/4885 |
| US-20050169993-A1 | Sustained-release formulation | ABCB11, SLC38A7, ABCG2 | LMNA 3032/4885GAA 1318/4885KDM4E 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.